索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]万艺 王群山.预激综合征合并心房颤动的临床诊治进展[J].国际心血管病杂志,2018,04:200-203.
点击复制

预激综合征合并心房颤动的临床诊治进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年04期
页码:
200-203
栏目:
综述
出版日期:
2018-07-25

文章信息/Info

Title:
-
作者:
万艺 王群山
Author(s):
-
关键词:
预激综合征;  心房颤动;  发病机制;  诊断;  治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.04.003
文献标识码:
-
摘要:
预激综合征合并心房颤动可增加患者猝死风险,其临床诊治一直受到关注。本文主要介绍预激综合征合并心房颤动的发病机制、诊断、风险评估、急诊与射频消融治疗的研究进展
Abstract:
-

参考文献/References


[1] Centurión OA, Shimizu A, Isomoto S, et al. Mechanisms for the genesis of paroxysmal atrial fibrillation in the Wolff Parkinson-White syndrome: intrinsic atrial muscle vulnerability vs. electrophysiological properties of the accessory pathway[J]. Europace, 2008, 10(3):294-302.
[2] Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome[J]. N Engl J Med, 2003, 349(19):1803-1811.
[3] Liu XP, Yan Q, Li H, et al. Ablation of ligament of marshall attenuates atrial vulnerability to fibrillation induced by inferior left atrial fat pad stimulation in dogs[J]. J Cardiovasc Electrophysiol, 2010, 21(9):1024-1030.
[4] Obeyesekere M, Gula LJ, Skanes AC, et al. Risk of sudden death in Wolff-Parkinson-White syndrome how high is the risk?[J]. Circulation, 2012, 125(5):659-660.
[5] Li JJ, Wei F, Chen JG, et al. Assessment of atrial fibrillation and vulnerability in patients with Wolff-Parkinson-White syndrome using two-dimensional speckle tracking echocardiography[J]. PLoS One, 2014, 9(11):e108315.
[6] Ehtisham J, Watkins H. Is Wolff-Parkinson-White syndrome a genetic disease?[J]. J Cardiovasc Electrophysiol, 2005, 16(11):1258-1262.
[7] Fatkin D, Santiago CF, Huttner IG, et al. Genetics of atrial fibrillation: state of the art in 2017[J]. Heart Lung Circ, 2017, 26(9):894-901.
[8] Zhang LP, Hui B, Gao BR. High risk of sudden death associated with a PRKAG2-related familial Wolff-Parkinson-White syndrome[J]. J Electrocardiol, 2011, 44(4):483-486.
[9] Spotnitz MD, Markowitz SM, Liu CF, et al. Mechanisms and clinical significance of adenosine-induced dormant accessory pathway conduction after catheter ablation[J]. Circ Arrhythm Electrophysiol, 2014, 7(6):1136-1143.
[10] Wolff L, Parkinson J, White PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. 1930[J]. Ann Noninvasive Electrocardiol, 2006, 11(4):340-353.
[11] Pappone C, Vicedomini G, Manguso F, et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients[J]. Circulation, 2014, 130(10):811-819.
[12] Janson CM, Shah MJ. Supraventricular tachycardia in adult congenital heart disease: mechanisms, diagnosis, and clinical aspects[J]. Card Electrophysiol Clin, 2017, 9(2):189-211.
[13] Long B, Koyfman A. Best clinical practice: emergency medicine management of stable monomorphic ventricular tachycardia [J]. J Emerg Med, 2017, 52(4):484-492.
[14] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society[J]. Circulation, 2014, 64(21):e1-e76.
[15] Simonian SM, Lotfipour S, Wall CA. Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation[J]. Intern Emerg Med, 2010, 5(5):421-426.
[16] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38):2893-2962.
[17] Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators[J]. N Engl J Med, 2000, 342(13):913-920.
[18] Conte G, Levinstein M, Sarkozy A, et al. The clinical impact of ajmaline challenge in elderly patients with suspected atrioventricular conduction disease[J]. Int J Cardiol, 2014, 172(2):423-427.
[19] Tischenko A, Fox DJ, Yee R, et al. When should we recommend catheter ablation for patients with the Wolff-Parkinson-White syndrome?[J]. Curr Opin Cardiol, 2008, 23(1):32-37.
[20] Della Bella P, Brugada P, Talajic M, et al. Atrial fibrillation in patients with an accessory pathway: importance of the conduction properties of the accessory pathway[J]. J Am Coll Cardiol, 1991, 17(6):1352-1356.
[21] Chen SA, Chiang CE, Tai CT, et al. Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia[J]. Circulation, 1996, 93(11):2023-2032.
[22] Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack a systematic review and meta-analysis[J]. Stroke, 2014, 45(2):520-526.
[23] Feng XF, Wang QS, Sun J, et al. Pulmonary vein antrum isolation of pre-excited atrial fibrillation[J]. Chin Med J, 2013, 126(14):2613-2619.
[24] 王传慧, 王群山. 对心房颤动电复律治疗的认识[J]. 中国介入心脏病学杂志, 2016, 24(4):221-224.
[25] Borregaard R, Lukac P, Gerdes C, et al. Radiofrequency ablation of accessory pathways in patients with the Wolff-Parkinson-White syndrome: the long-term mortality and risk of atrial fibrillation[J]. Europace, 2015, 17(1):117-122.
[26] Chen M, Feng X, Sun J, et al. Risk factors responsible for atrial fibrillation development between symptomatic patients with concealed or manifest atrioventricular accessory pathways[J]. Int J Cardiol Heart Vasc, 2015, 7:69-75.
[27] Deal BJ, Keane JF, Gillette PC, et al. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up[J]. J Am Coll Cardiol, 1985, 5(1):130-135.
[28] Brembilla-Perrot B, Popescu I, Huttin O, et al. Risk of atrial fibrillation according to the initial presentation of a preexcitation syndrome[J]. Int J Cardiol, 2012, 157(3):359-363.

备注/Memo

备注/Memo:
作者单位:200025 上海交通大学医学院附属新华医院心血管内科
通信作者:王群山,Email:gjxxgbzzs@163.com
更新日期/Last Update: 2018-07-30